(MENAFN - Investor Brand Network) Silo Pharma (NASDAQ: SILO) , a biopharmaceutical company developing innovative therapeutics, has initiated a pharmacokinetic ("PK") and tolerability study for its dissolvable ketamine-based implant, SP-26, in collaboration with AmplifyBio. The study will evaluate SP-26, aimed at treating chronic pain and fibromyalgia, in a minipig model over three weeks, focusing on absorption, distribution, metabolism, and excretion ("ADME"). Silo CEO Eric Weisblum highlighted the progress made through earlier analytical and manufacturing tests, emphasizing this study as a key milestone. AmplifyBio expressed its commitment to supporting Silo in advancing SP-26's safety evaluation.

To view the full press release, visit

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions and central nervous system ("CNS") diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug-delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting post-traumatic stress disorder ("PTSD") and stress-induced anxiety disorders. SP-26 is a time-release, ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo's two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis ("MS"). Silo's research and development programs are conducted through collaborations with universities and independent laboratories. For more information about the company, visit

.

NOTE TO INVESTORS:
The latest news and updates relating to SILO are available in the company's newsroom at

About InvestorWire

InvestorWire
("IW") is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within
the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:
/Disclaimer

InvestorWire
Los Angeles, CA

310.299.1717 Office
[email protected]

InvestorWire is powered by
IBN

MENAFN18122024000224011066ID1109008521

COMTEX_461016651/2604/2024-12-19T03:58:10